Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with P
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2024 | POLYETHYLENE GLYCOL 300 | INTRAVENOUS | INJECTION | 2768mg | Correction | ||
| Q4 2024 | POLYETHYLENE GLYCOL 300 | INTRAVENOUS | INJECTION | 2592mg | Correction | ||
| Q3 2024 | POLYETHYLENE GLYCOL 400 | INTRAVENOUS | INJECTION, SOLUTION | 28217mg | Correction | ||
| Q4 2024 | POLYETHYLENE GLYCOL 400 | INTRAVENOUS | INJECTION, SOLUTION | 24186mg | Correction | ||
| Q3 2024 | POLYVINYL ALCOHOL | ORAL | TABLET, ORALLY DISINTEGRATING | 6mg | Correction | ||
| Q4 2024 | POLYVINYL ALCOHOL | ORAL | TABLET, ORALLY DISINTEGRATING | 2mg | Correction | ||
| Q3 2024 | PROPYLENE GLYCOL | TOPICAL | CREAM, AUGMENTED | 30.00 %w/w | Correction | ||
| Q4 2024 | PROPYLENE GLYCOL | TOPICAL | CREAM, AUGMENTED | 8.00 %w/w | Correction | ||
| Q3 2024 | PROSOLV ODT | ORAL | TABLET, ORALLY DISINTEGRATING | 858mg | Correction | ||
| Q4 2024 | PROSOLV ODT | ORAL | TABLET, ORALLY DISINTEGRATING | 361mg | Correction | ||
| Q4 2024 | PARAFFIN | ORAL | CAPSULE | 43.32 mg | 68mg | Deletion | |
| Q4 2024 | PEG-100 MONOSTEARATE | TOPICAL | CREAM, AUGMENTED | 0.50 %w/w | Deletion | ||
| Q4 2024 | PHENYLMERCURIC ACETATE | TOPICAL | CREAM | 0.01 %w/w | Deletion | ||
| Q4 2024 | PHENYLMERCURIC ACETATE | VAGINAL | CREAM | 0.01 %w/w | Deletion | ||
| Q4 2024 | PHOSPHORIC ACID | ORAL | SYRUP | 6.40 mg/ 5.00 ml | Deletion | ||
| Q4 2024 | PHOSPHORIC ACID | TOPICAL | CREAM, AUGMENTED | 0.02 %w/w | Deletion | ||
| Q4 2024 | POLYETHYLENE GLYCOL 3000 | ORAL | TABLET, EXTENDED RELEASE | 3.00 mg | 24mg | Deletion | |
| Q4 2024 | POLYETHYLENE GLYCOL 4000 | ORAL | SYRUP | 370.00 mg/ 5.00 ml | Deletion | ||
| Q4 2024 | POLYETHYLENE OXIDE 100000 | ORAL | TABLET | 192.66 mg | Deletion | ||
| Q4 2024 | PROSOLV ODT | ORAL | TABLET, EXTENDED RELEASE | 429.14 mg | 791mg | Deletion | |
| Q3 2024 | PARAFFIN | ORAL | CAPSULE, EXTENDED RELEASE | 50.00 mg | MDE Replacement | ||
| Q4 2024 | PARAFFIN | ORAL | CAPSULE, EXTENDED RELEASE | 68mg | MDE Replacement | ||
| Q3 2024 | PEG-120 METHYL GLUCOSE DIOLEATE | TOPICAL | SHAMPOO | 1.80 %w/w | MDE Replacement | ||
| Q4 2024 | PEG-120 METHYL GLUCOSE DIOLEATE | TOPICAL | SHAMPOO | 300mg | MDE Replacement | ||
| Q3 2024 | PHENONIP | TOPICAL | GEL | 0.04 %w/w | MDE Replacement | ||
| Q4 2024 | PHENONIP | TOPICAL | GEL | 1mg | MDE Replacement | ||
| Q3 2024 | POLYETHYLENE GLYCOL 400 | NASAL | SPRAY, METERED | 200.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2024 | POLYETHYLENE GLYCOL 400 | NASAL | SPRAY, METERED | 320mg | MDE Replacement | ||
| Q3 2024 | POLYETHYLENE OXIDE 100000 | ORAL | TABLET, EXTENDED RELEASE | 96.33 mg | MDE Replacement | ||
| Q4 2024 | POLYETHYLENE OXIDE 100000 | ORAL | TABLET, EXTENDED RELEASE | 385mg | MDE Replacement | ||
| Q3 2024 | POLYSORBATE 20 | NASAL | SPRAY, METERED | 25.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2024 | POLYSORBATE 20 | NASAL | SPRAY, METERED | 40mg | MDE Replacement | ||
| Q3 2024 | POLYSORBATE 60 | VAGINAL | CREAM | 5.00 %w/w | MDE Replacement | ||
| Q4 2024 | POLYSORBATE 60 | VAGINAL | CREAM | 50mg | MDE Replacement | ||
| Q3 2024 | POLYSORBATE 80 | OPHTHALMIC | SUSPENSION | 0.10 %w/w | MDE Replacement | ||
| Q4 2024 | POLYSORBATE 80 | OPHTHALMIC | SUSPENSION | 1mg | MDE Replacement | ||
| Q3 2024 | PROMULGEN G | TOPICAL | LOTION | 2.16 %w/w | MDE Replacement | ||
| Q4 2024 | PROMULGEN G | TOPICAL | LOTION | 17mg | MDE Replacement | ||
| Q3 2024 | PROPYLENE GLYCOL | NASAL | SPRAY, METERED | 50.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2024 | PROPYLENE GLYCOL | NASAL | SPRAY, METERED | 80mg | MDE Replacement | ||
| Q3 2024 | PROPYLENE GLYCOL MONOSTEARATE | TOPICAL | CREAM | 9.30 %w/w | MDE Replacement | ||
| Q4 2024 | PROPYLENE GLYCOL MONOSTEARATE | TOPICAL | CREAM | 257mg | MDE Replacement | ||
| Q3 2024 | PROPYLPARABEN | VAGINAL | CREAM | 0.10 %w/w | MDE Replacement | ||
| Q4 2024 | PROPYLPARABEN | VAGINAL | CREAM | 3mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Bioequivalence
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: September 19, 2024
Database Last Updated: October 19, 2024